Just as it is for terminally ill cancer patients, time is of the essence for people in the early stages of Alzheimer’s disease. Thus, the clinical meaningfulness of Eli Lilly and Co.’s donanemab is the time it gives patients before the disease progresses, Reisa Sperling, a neurology professor at Harvard Medical School and director of the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital, told the U.S. FDA’s Peripheral and Central Nervous System Drugs Advisory Committee June 10.

The first patenting from San Francisco-based Ananya Health Inc. describes its development of a closed-loop cryoablation platform to freeze abnormal cells before they become cervical cancer. The company’s device achieves ablative temperatures without consumable gas, making the procedure portable, battery-powered, and ten times cheaper than traditional cryoablation.

A survey of 1,025 consumers conducted by remote patient monitoring company Vivalink Inc. found that 84% of respondents would be willing to participate in hospital-at-home monitoring if it allowed them to leave the hospital earlier. Further, of those who had participated in a hospital-at-home program, 84% reported a positive experience.

Aktiia SA recently received a CE mark for Calfree, its optical blood pressure monitoring technology that does not require calibration with a traditional cuff. The Calfree system can be integrated into a wide range of third-party devices, significantly improving hypertension management and as a result the quality of patients’ lives.

In May, the value of med-tech deals dropped to $85.78 million, marking a 50% decrease from April's $172.37 million but exceeding March's $27 million. The monthly average for deal value in 2024 now stands at $129.7 million, an 84% decline compared to the 2023 monthly average of $886.13 million.